Novak F, Bajwa HM, Coia JE, Nilsson AC, et al. Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses. J Neurol Neurosurg Psychiatry 2023 Apr 25:jnnp-2022-330757.
PMID: 37185261